With some neuro targets in mind, AbbVie gets Sosei's drug discovery engine churning again
AbbVie has got more work for Sosei Heptares.
A year and a half after breaking off a legacy Allergan pact involving a slate of Sosei neurology candidates, AbbVie has drawn up a whole slew of new neuro targets it wants to direct Sosei’s G protein-coupled receptor expertise and structure-based drug design savviness toward.
The heavily back-ended deal starts with a $40 million upfront and $40 million more in near-term milestones but is tied to biobucks adding up to $1.2 billion.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.